Overexpression of Glypican 3 Promotes Proliferation, Regulates Cell Cycle Progression, and Inhibits Apoptosis of Human Fetal Osteoblastic Cell Line 1.19

Overexpression of Glypican 3 Promotes Proliferation, Regulates Cell Cycle Progression, and Inhibits Apoptosis of Human Fetal Osteoblastic Cell Line 1.19
复制标题

磷脂酰肌醇蛋白聚糖 3 的过表达促进增殖、调节细胞周期进展并抑制人胎儿成骨细胞系 1.19 的凋亡

DOI:
10.1097/scs.0000000000003861
复制
发表时间:
2017-09-01
影响因子:
0.9
通讯作者:
Mu, Xiongzheng
Mu, Xiongzheng
中科院分区:
医学4区
文献类型:
--
作者:
Cai, Tianyi;Wu, Yingzhi;Mu, Xiongzheng

文献摘要

被引文献

相似文献

摘要颅骨融合是一种复杂的疾病,涉及颅顶缝过早融合,缺乏理想的治疗方法。以往的研究表明,在综合征型颅骨融合症患者中,成骨细胞增殖率降低,Glypical3(GPC3)表达下调。本研究采用定量和定性分析相结合的方法,研究GPC3对人胎儿成骨细胞株hFOB 1.19的作用。72 后获得绿色荧光蛋白图像的慢病毒转染率。Western Blot和实时定量聚合酶链式反应分析结果表明,重组慢病毒LV-GPC3-GFP在hFOB 1.19细胞中高表达GPC3。CCK-8比色法检测细胞增殖,流式细胞仪检测细胞周期进程和细胞凋亡。结果表明,GPC3能促进细胞活力,诱导细胞周期进入S期,抑制细胞凋亡。这些发现为理解颅缝早闭的发病机制提供了新的思路。这也为通过靶向GPC3治疗颅缝融合症提供了新的见解。
Abstract Craniosynostosis is a complex disease condition, which involves premature fusion of cranial vault sutures and lacks desirable treatment. Previous studies have demonstrated decreased proliferation rate of osteoblasts and downregulated expression of glypican 3 (GPC3) in syndromic craniosynostosis patients. In this study, quantitative and qualitative analysis were utilized to assess the effect of GPC3 in human fetal osteoblastic cell line, hFOB 1.19. Lentiviral transfection efficiency with green fluorescent protein images was obtained after 72 hours. Western Blot and quantitative real-time polymerase chain reaction analysis results indicated that GPC3 was overexpressed in hFOB 1.19 cells transfected with recombinant lentivirus LV-GPC3-GFP. Cell proliferation was assessed by CCK-8 assay and cell cycle progression and apoptosis were analyzed by flow cytometric assay. Results revealed that GPC3 promoted cell viability, induced cell cycle entry into S phase, and inhibited cell apoptosis. These findings provide novel ideas in understanding the pathogenesis of craniosynostosis. It also provides novel insights in the treatment of craniosynostosis by targeting GPC3.